from Nature Biotechnology

CRISPR-Cas9 claim sets and the potential to stifle innovation


Our national IP system can be an enabler or a barrier to revolutionary genome editing technology as reflected in our recent article in Nature Biotechnology. Read more reflections about how overly broad claims of genome editing could create another era of multinational dominance in genomics.